From Culture to Curve: Performing Effective Malaria Drug Assays

 Performing Drug Assays in Plasmodium falciparum Cell Lines

Drug assays are a cornerstone of malaria research, enabling scientists to measure how well antimalarial compounds inhibit Plasmodium falciparum growth. These assays help determine drug potency (e.g., IC₅₀ values), resistance levels, and efficacy of new or existing treatments.

This guide walks through the typical steps for performing a drug assay using cultured P. falciparum parasites.

Choosing Between Single-Dose and Serial-Dilution Drug Assays

In malaria research, two main strategies are used to assess drug efficacy against Plasmodium falciparum: serial-dilution assays and single-dose assays.

• Serial-dilution assays measure parasite growth inhibition across a range of drug concentrations. These generate dose–response curves and allow for precise calculation of metrics like IC₅₀.

• Single-dose assays, on the other hand, involve exposing parasites to one fixed drug concentration. These are ideal for high-throughput screening, field surveillance, or initial triage of compound libraries.

Each approach has its place, depending on the objective—whether it's discovering new leads, confirming resistance, or comparing parasite lines.

Example: Performing Serial Dilutions in Malaria Drug Assays

A typical method for assessing drug sensitivity in P. falciparum is the twofold serial dilution technique, often performed with dihydroartemisinin (DHA) or other antimalarials.

Here’s a step-by-step example from literature:

Study Protocol Overview (Leidenberger et al.):

1. Synchronized parasites (ring stage, 0.5–1% parasitemia, 1.5–2% hematocrit)

2. Prepare drug stock (e.g., 1,000 nM DHA)

3. Perform two fold serial dilutions:

• 1,000 nM → 500 nM → 250 nM → 125 nM → 62.5 nM → ... down to ~1 nM

4. Add diluted drugs to 96-well microplates containing parasite cultures (100–200 µL per well)

5. Incubate 48–72 hours at 37 °C with appropriate gas mix (5% CO₂, 5% O₂, 90% N₂)

6. Measure growth inhibition using SYBR Green I fluorescence assay

7. Analyze fluorescence values and plot dose–response curves in software like GraphPad Prism to determine IC₅₀

This method is widely used in both academic and surveillance settings.

Other Examples from Literature:

• Burkina Faso Study: Used DHA concentrations ranging from 0.2–64 nM, quantified by HRP-2 ELISA after 72 h incubation.

• Thailand Field Assay: Applied seven-point twofold dilutions with [3H]-hypoxanthine incorporation after 42 h to assess parasite growth.

1. Preparing the Parasite Culture

• Synchronized parasites (usually ring-stage) are preferred for consistency

• Start with:

• 0.5% to 1% parasitemia

• 1.5% to 2% hematocrit

• Use a 96-well microplate for high-throughput and replicates

• Total volume per well is typically 100–200 µL

2. Drug Preparation and Plate Setup

• Prepare a serial dilution of the test drug across a wide concentration range

• Add diluted drug to wells (e.g., 10 concentrations, each in duplicate or triplicate)

• Include:

• Negative controls (no drug)

• Positive controls (e.g., known drug like chloroquine or artemisinin)

3. Incubation

• Incubate plates for 48–72 hours at 37°C

• Maintain standard gas mixture (5% CO₂, 5% O₂, 90% N₂)

• Do not disturb plates during incubation

4. Readout Methods: Measuring Parasite Growth

Choose a method to assess how much the parasite grew in each well:

a. SYBR Green I Fluorescence Assay (most common)

• Add lysis buffer with SYBR Green I dye after incubation

• Incubate for ~1 hour in the dark

• Measure fluorescence with a plate reader (excitation: 485 nm, emission: 535 nm)

• Fluorescence intensity ≈ parasite DNA content

b. [3H]-Hypoxanthine Incorporation

• Add radioactive hypoxanthine at beginning of incubation

• Measure uptake into parasite DNA using scintillation counter

• High sensitivity, but requires radioactivity handling

c. pLDH Assay

• Measures parasite lactate dehydrogenase enzyme

• Colorimetric (ELISA-based)

• Suitable for non-radioactive workflows

d. Microscopy

• Prepare Giemsa-stained smears

• Manually count parasitemia (slow, but useful for confirmation)

5. Data Analysis

• Plot dose-response curves (drug concentration vs. parasite growth)

• Use curve-fitting software (e.g., GraphPad Prism) to determine:

• IC₅₀: Concentration that inhibits 50% of parasite growth

• IC₉₀, EC₅₀ for other applications

• Compare IC₅₀s to standard reference values to assess resistance

Specialized Assays

• Ring-stage survival assay (RSA): Detects artemisinin resistance by exposing early rings for 6h then washing off the drug and incubating for 66h

• Delayed death assay: For drugs targeting apicoplasts (e.g., doxycycline); effect seen in next parasite cycle

• Checkerboard assay: Assesses drug combinations for synergy or antagonism

When Only One Drug Concentration Is Used

Single-point drug assays are used in several research and public health contexts:

High-Throughput Screening (HTS)

• Thousands of compounds tested at one fixed dose (e.g., 1 µM)

• Hits are compounds that show high inhibition (>80%)

Resistance Surveillance

• Ring-stage Survival Assay (RSA) uses a fixed 700 nM dihydroartemisinin dose

• Often used to detect field resistance trends with fixed drug panels

Functional Genomics & Phenotyping

• Gene knockout or mutant lines tested at one known inhibitory dose (e.g., IC₉₀)

• Used to compare relative survival/resistance

Single-dose assays are time-efficient and cost-effective, especially for large-scale studies or preliminary screens.

Summary

Step	Description
1. Setup	Synchronized culture in microplate
2. Drug dilution	Serially dilute and dispense in wells
3. Incubation	48–72h with gas mix at 37°C
4. Readout	Fluorescence, radiolabel, ELISA, or microscopy
5. Analysis	Calculate IC₅₀, determine resistance

References:

1. Leidenberger, M., Voigtländer, C., Simon, N., & Kappes, B. (2017). SYBR® Green I-Based Fluorescence Assay to Assess Cell Viability of Malaria Parasites for Routine Use in Compound Screening. Methods in molecular biology (Clifton, N.J.), 1601, 97–110. https://doi.org/10.1007/978-1-4939-6960-9_9
   
   

2. Ringwald P, Same Okobo A, Keundjian A, Kedy Mangamba D, Basco LK: Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 1: Surveillance of in vitro and in vivo resistance Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. Trop Med Int Health. 2000, 5: 612-629. 10.1046/j.1365-3156.2000.00613.x.
   
   

3. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, White NJ, Nosten F: The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006, 62: 1021-1031. 10.1007/s00228-006-0199-7.
   
   

4. Fakeye TO, Fehintola FA, Ademowo OG, Walker O: Therapeutic monitoring of chloroquine in pregnant women with malaria. West Afr J Med. 2002, 21: 286-287.
   
   

5. Chulay, J. D., Haynes, J. D., & Diggs, C. L. (1983). Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Experimental parasitology, 55(1), 138–146. https://doi.org/10.1016/0014-4894(83)90007-3
   
   

6. WHO Methods Manual: In Vitro and Ex Vivo Antimalarial Drug Efficacy Testing, 2023.

June 24, 2025 Tags : DHA , IC50 , lab protocol , malaria drug assay , Plasmodium falciparum , serial dilution , SYBR Green assay

Subscribe by Email

Follow Updates Articles from This Blog via Email